Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2

Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. In this cohort analysis, we use linked data from Catalonia (Spain), where those aged <60 who rece...

Full description

Bibliographic Details
Main Authors: Argimon, J.M (Author), Ballo, E. (Author), Cabezas, C. (Author), Coma, E. (Author), Feng, S. (Author), Fina, F. (Author), Hermosilla, E. (Author), Martínez, M. (Author), Medina-Peralta, M. (Author), Méndez-Boo, L. (Author), Prieto-Alhambra, D. (Author), Xie, J. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Subjects:
adverse event
aged
Aged
BNT162 Vaccine
Catalonia
comparative study
COVID-19
epidemiology
gene
gene expression
human
Humans
immune response
prevention and control
safety
SARS-CoV-2
Spain
vaccination
Vaccination
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items